BNP Paribas Arbitrage SA Boosts Holdings in ResMed Inc. (RMD)
BNP Paribas Arbitrage SA raised its position in ResMed Inc. (NYSE:RMD) by 31.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 102,887 shares of the medical equipment provider’s stock after purchasing an additional 24,785 shares during the period. BNP Paribas Arbitrage SA owned about 0.07% of ResMed worth $7,918,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in ResMed by 17.3% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 42,898 shares of the medical equipment provider’s stock valued at $3,340,000 after purchasing an additional 6,316 shares during the last quarter. Delta Lloyd Asset Management N.V. acquired a new stake in shares of ResMed during the second quarter valued at $6,194,000. Prudential Financial Inc. boosted its stake in shares of ResMed by 50.5% during the second quarter. Prudential Financial Inc. now owns 131,997 shares of the medical equipment provider’s stock valued at $10,279,000 after acquiring an additional 44,266 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of ResMed by 21.4% during the second quarter. Victory Capital Management Inc. now owns 21,597 shares of the medical equipment provider’s stock valued at $1,682,000 after acquiring an additional 3,809 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in shares of ResMed by 2.9% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 47,056 shares of the medical equipment provider’s stock valued at $3,665,000 after acquiring an additional 1,306 shares during the last quarter. 58.86% of the stock is currently owned by institutional investors.
A number of analysts recently commented on the company. BMO Capital Markets increased their price objective on ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a research note on Wednesday, August 2nd. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a research note on Wednesday, August 2nd. Zacks Investment Research lowered ResMed from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Credit Suisse Group lowered ResMed from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Finally, Barclays PLC increased their price objective on ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a research note on Friday, October 27th. Four research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $67.57.
Shares of ResMed Inc. (NYSE:RMD) opened at $84.98 on Friday. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50. ResMed Inc. has a 12 month low of $57.45 and a 12 month high of $87.81. The stock has a market capitalization of $11,955.40, a PE ratio of 29.35, a PEG ratio of 1.87 and a beta of 0.79.
ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The business had revenue of $523.66 million during the quarter, compared to analyst estimates of $506.08 million. During the same quarter last year, the firm earned $0.62 earnings per share. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. analysts expect that ResMed Inc. will post 3 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be paid a $0.35 dividend. The ex-dividend date is Wednesday, November 8th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.65%. ResMed’s dividend payout ratio (DPR) is currently 56.68%.
In other ResMed news, Director Peter C. Farrell sold 118,392 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $82.70, for a total transaction of $9,791,018.40. Following the completion of the sale, the director now owns 306,615 shares in the company, valued at approximately $25,357,060.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Peter C. Farrell sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $76.74, for a total value of $1,534,800.00. Following the sale, the director now owns 314,800 shares of the company’s stock, valued at approximately $24,157,752. The disclosure for this sale can be found here. In the last quarter, insiders sold 201,234 shares of company stock valued at $16,339,637. Insiders own 1.77% of the company’s stock.
WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/bnp-paribas-arbitrage-sa-boosts-holdings-in-resmed-inc-rmd/1709374.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.